P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemiaKevin Lin, Kris C. Wood, Mariaelena Pierobon et al.|Nature Cancer|2022Cited by 42
Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosisShane T. Killarney, Kris C. Wood, Rachel Washart et al.|Nature Communications|2023Cited by 37
Sublethal engagement of apoptotic pathways in residual cancerShane T. Killarney, Kris C. Wood, Stephen W. G. Tait et al.|Trends in Cell Biology|2023Cited by 30
Drug dependence in cancer is exploitable by optimally constructed treatment holidaysJeff Maltas, Kevin B. Wood, Shane T. Killarney et al.|Nature Ecology & Evolution|2023Cited by 27
Targeting a lineage-specific PI3Kɣ–Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader moleculeLoïs Kelly, Alexandre Puissant, Justine C. Rutter et al.|Nature Cancer|2024Cited by 25